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Summary
Background Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome
(KS) and xeroderma pigmentosum complementation group C (XPC) are three
cancer-prone genodermatoses whose causal genetic mutations cannot fully
explain, on their own, the array of associated phenotypic manifestations. Recent
evidence highlights the role of the stromal microenvironment in the pathology
of these disorders.
Objectives To investigate, by means of comparative gene expression analysis, the
role played by dermal fibroblasts in the pathogenesis of RDEB, KS and XPC.
Methods We conducted RNA-Seq analysis, which included a thorough examination
of the differentially expressed genes, a functional enrichment analysis and a
description of affected signalling circuits. Transcriptomic data were validated at
the protein level in cell cultures, serum samples and skin biopsies.
Results Interdisease comparisons against control fibroblasts revealed a unifying sig-
nature of 186 differentially expressed genes and four signalling pathways in the
three genodermatoses. Remarkably, some of the uncovered expression changes
suggest a synthetic fibroblast phenotype characterized by the aberrant expression
of extracellular matrix (ECM) proteins. Western blot and immunofluorescence
in situ analyses validated the RNA-Seq data. In addition, enzyme-linked immunosor-
bent assay revealed increased circulating levels of periostin in patients with RDEB.
Conclusions Our results suggest that the different causal genetic defects converge
into common changes in gene expression, possibly due to injury-sensitive events.
These, in turn, trigger a cascade of reactions involving abnormal ECM deposition
and underexpression of antioxidant enzymes. The elucidated expression signature
provides new potential biomarkers and common therapeutic targets in RDEB,
XPC and KS.
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What’s already known about this topic?
• Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and
xeroderma pigmentosum complementation group C (XPC) are three genoder-
matoses with high predisposition to cancer development.
• Although their causal genetic mutations mainly affect epithelia, the dermal
microenvironment likely contributes to the physiopathology of these disorders.
What does this study add?
• We disclose a large overlapping transcription profile between XPC, KS and RDEB
fibroblasts that points towards an activated phenotype with high matrix-synthetic
capacity.
• This common signature seems to be independent of the primary causal deficiency,
but reflects an underlying derangement of the extracellular matrix via transforming
growth factor-b signalling activation and oxidative state imbalance.
What is the translational message?
• This study broadens the current knowledge about the pathology of these diseases
and highlights new targets and biomarkers for effective therapeutic intervention.
• It is suggested that high levels of circulating periostin could represent a potential
biomarker in RDEB.
The progress made in molecular genetics has greatly con-
tributed to identifying the primary causes of a large number
of heritable skin diseases.1 However, these findings do not
always explain by themselves the complex phenotypic mani-
festations observed in cancer-prone genodermatoses, such as
recessive dystrophic epidermolysis bullosa (RDEB), Kindler
syndrome (KS) and xeroderma pigmentosum complementa-
tion group C (XPC). RDEB is caused by loss-of-function
mutations in the COL7A1 gene, which encodes type VII col-
lagen (C7) anchoring fibrils, structures that connect the epi-
dermal basement membrane to the dermal tissue. C7
deficiency causes loss of dermoepidermal adhesion, resulting
in blister formation, scarring and aggressive carcinoma
development.2
KS results from recessive mutations in the FERMT1 gene,
encoding kindlin-1. This protein mediates anchorage between
the actin cytoskeleton and the extracellular matrix (ECM) via
focal adhesions. KS is characterized clinically by early-age acral
skin blisters, photosensitivity and high risk of mucocutaneous
malignancies.3–5 XPC is characterized by mutations in the XPC
gene, which cause a severe deficiency in the nucleotide exci-
sion repair pathway. Patients with XPC are highly sensitive to
ultraviolet radiation and have a very high risk of developing
skin tumours in sun-exposed areas, mostly basal and squa-
mous cell carcinomas arising from epidermal keratinocytes,
and malignant melanomas.6 Patients with XPC also have a
high risk of developing tumours in internal organs not
exposed to sunlight.7
Besides cancer susceptibility, other common clinical signs to
the three genodermatoses are inflammation and premature
skin ageing.8–10 Although the specific primary and subsequent
genetic alterations at the epidermal level are likely to be major
drivers for carcinogenesis in these disorders, an altered stroma
may play a facilitating role towards tumour development and
malignant progression.
Robust data, gathered mainly from omics studies of patient
cells and mouse models, underscore the role of aberrant ECM
deposition, leading to progressive fibrosis and cutaneous squa-
mous cell carcinoma (cSCC) in RDEB. This process appears to
be mediated by the dermal fibroblasts, which acquire molecu-
lar changes similar to those present in the tumour microenvi-
ronment (i.e. cancer-associated fibroblasts; CAFs).11 Less is
known in this regard for KS and XPC, although marginal
evidence indicates that fibroblasts may also be relevant in the
disease pathogenesis.12–15 Here we demonstrate through RNA-
Seq analysis and expression validation of relevant genes that
RDEB, XPC and KS fibroblasts allow establishment of a com-
mon profibrotic microenvironment that could favour disease
progression and cancer.
Materials and methods
Sample collection and cell culture
All procedures were approved by the ethics committee of La Paz
University Hospital (code HULP: PI-1602) and were conducted
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in accordance with the Declaration of Helsinki and subsequent
revisions. Skin biopsies from unaffected areas of seven healthy
donors, 11 patients with RDEB, four patients with KS and four
patients with XPC were obtained after written informed consent
was obtained. Fibroblasts were isolated by mechanical and
enzymatic digestion as previously described.16 They were cul-
tured in Dulbecco’s Modified Eagle’s Medium supplemented
with 10% fetal bovine serum (both Thermo Fisher Scientific,
Waltham, MA, U.S.A. and Invitrogen, Carlsbad, CA, U.S.A.) and
1% Antibiotic-Antimycotic (Thermo Fisher Scientific). The
characteristics of the patients and controls can be seen in
Table S1 (see Supporting Information). All cells used were at
early three to seven passages (see Table S1).
RNA extraction
Culture medium was changed 24 h before harvesting the cells.
Total RNA was isolated from confluent primary fibroblasts
using an RNeasy Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol recommendations. RNA concen-
tration and quality were determined on a NanoDrop Spec-
trophotometer (Thermo Scientific Inc.) and integrity was
verified with a Bioanalyzer 2100 (Agilent, Santa Clara, CA,
U.S.A.). The RNA integrity number in all cases was higher
than 85. To minimize technical variability, RNA extracts from
four technical replicates of each sample were mixed.
RNA-Seq data processing
cDNA libraries were generated for each sample using the TruSeq
RNA Sample Preparation Kit (Illumina, San Diego, CA, U.S.A.)
according to the recommended protocol. Ligation and library
integrity were verified using an Agilent Bioanalyzer 2100. Sam-
ple libraries ligated with unique adapter sequences were multi-
plexed six to a lane and were sequenced by Edinburgh
Genomics (Edinburgh, U.K.) using Illumina HiSeq HO v4 125
paired end sequencing. Quality control analysis on the resulting
FASTQ files was performed using FastQC (Babraham Bioinfor-
matics, Cambridge, U.K.). Reads were adapter trimmed using
cutadapt version 13 (https://pypi.org/project/cutadapt/13)
with the parameters -q 30 -m 50 -a AGATCGGAAGAGC.
Trimmed reads were aligned to Ensembl version 3881 of the
Homo sapiens genome with TopHat2 version 2013 (https://ccb.
jhu.edu/software/tophat) using default parameters, except ‘-r -
70 -mate-std-dev 75’ to specify insert sizes. The BAM files were
sorted by name using Picard-tools version 1115 SortSam
(https://broadinstitute.github.io/picard). Read counts were
generated using HTSeq-count version 060 in unstranded mode
(https://htseq.readthedocs.io) and Python version 273, with
parameters -m union -i gene_id -t exon. Raw and processed data
are stored at the National Center for Biotechnology Information’s
Gene Expression Omnibus, accession code https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE119501.
RNA-Seq data were normalized using the Trimmed Mean of
M-values.17 An adjustment for possible batch effects was per-
formed using the R package ComBat.18 The transcripts that had
an average expression per condition < 1 count per million and a
coefficient of variation per condition > 100% were filtered.
Differential expression analysis was performed with the Biocon-
ductor package edgeR.19 The conventional multiple-testing
P-value correction procedure proposed by Benjamini and Hoch-
berg was used to derive adjusted P-values.20 Enrichment analysis
was carried out for the gene ontology terms using the Babe-
lomics suite21 and DAVID bioinformatic resources.22
Pathway activity analysis and protein–protein interaction
The signalling circuit activity analysis method,23 as imple-
mented in the hiPathia R package (https://github.com/babelo
mics/hipathia), was applied to all disease vs. healthy control
comparisons. Under this modelling schema, signalling circuits
are defined within Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways as the chain of proteins that connect a
receptor protein to an effector protein that triggers specific
cellular activities. The signal is propagated from the receptor
protein along the proteins that compose the circuit by a recur-
sive formula that takes into account the activity of both activa-
tor and inhibitor proteins. Finally, the list of the common
dysregulated genes in all disease vs. control comparisons was
uploaded to STRING,24 a database that represents the known
protein–protein interactions (PPIs). The minimum required
interaction score was set to > 07, allowing only high-confi-
dence connections between nodes.
Western blot analysis
Primary fibroblasts, serum starved for 24 h, were lysed with
25-mmol L1 Tris-HCl (pH 74), 100-mmol L1 NaCl, 1%
Nonidet P-40 and protease inhibitor cocktail (Roche Diagnos-
tics Limited, Burgess Hill, U.K.). The extracts were cleared of
cellular debris by centrifugation at 16 000 g for 15 min at
4 °C. Protein extracts were electrophoresed on sodium dode-
cylsulfate polyacrylamide 4–12% Bis-Tris gel and transferred
onto nitrocellulose membranes. The membranes were blocked
with 5% nonfat milk powder in 1X Tris-buffered saline for
1 h at room temperature and incubated overnight with one of
the following antibodies: antitenascin C (MAB2138; R&D Sys-
tems Inc., Minneapolis, MN, U.S.A.), anti-bIG-H3 (D31B8;
Cell Signaling Technology, Beverly, MA, U.S.A.), anti-
ALDH1A1 (EP1933Y; Abcam, Cambridge, U.K.), antiperiostin
(sc-398631) antifibulin-1 (sc-25281), anti-TGase2 (sc-48387)
and anti-GAPDH (sc-25778; all Santa Cruz Biotechnology,
Santa Cruz, CA, U.S.A.). Detection was performed using horse-
radish peroxidase-conjugated secondary antibodies and a
chemiluminescent detection assay (SuperSignal West, Thermo
Fisher Scientific). Three independent experiments were per-
formed for each patient sample and control.
Immunofluorescence analysis
Skin cryosections from three healthy donors, two patients with
RDEB and two patients with KS were immunostained against
© 2019 The Authors. British Journal of Dermatology
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tenascin C (MAB2138) and periostin (sc-398631). Fluores-
cence quantification was measured using the ImageJ program
(https://imagej.nih.gov/ij). Student’s t-test was applied to
compare the fluorescence intensity/area means of samples,
using GraphPad Prism 504 (GraphPad Software, La Jolla, CA,
U.S.A.).
Enzyme-linked immunosorbent assay
Serum samples from 16 patients with RDEB and 10 healthy
donors (Table S1b; see Supporting Information) were anal-
ysed using a human periostin enzyme-linked immunosor-
bent assay kit (EHPOSTN-PL; Thermo Fisher Scientific)
according to the manufacturer’s protocol. The absorbance
was measured at 450 nm and 550 nm with a microtitre
plate reader (Tecan Genios Pro; Tecan Austria GmbH,
Gr€odig, Austria). The D’Agostino–Pearson omnibus test was
applied to determine whether the values had a normal dis-
tribution. An unpaired t-test with Welch’s correction was done
to determine the statistical significance between patients with
RDEB and controls (in GraphPad Prism 504). Two independent
experiments were performed for each patient sample and for
controls.
Results
Patients with genodermatoses and mutations
Patients were screened for COL7A1, XPC and FERMT1 specific
mutations, according to the diagnosed disease (Table S1a; see
Supporting Information). All patients with RDEB were
homozygous for a COL7A1 recurrent mutation (c.6527insC),
leading to a premature termination codon.25 All of the
screened patients with XPC carried a homozygous frameshift
mutation (c.1643_1644delTG) in XPC, resulting in a prema-
ture termination codon. Finally, patients with KS were the
most heterogeneous group, with three different homozygous
mutations in FERMT1. Sample KS1 produced altered splicing
due to insertion of a new triplet (c.1371+4>G), KS2 has a
missense variant (c.1198T>C) and KS3 has a frameshift muta-
tion (c.676dupC).
Identification of common expression signatures linked to
fibroblast activation and extracellular matrix deposition
RNA-Seq counts were obtained for primary fibroblasts isolated
from three healthy donors, nine patients with RDEB, three
patients with KS and three patients with XPC. In total 22 970
transcripts, identified by their Ensembl IDs, were obtained for
each sample after data quality assessment and normalization
(Table S2; see Supporting Information). The observed arrange-
ment of the samples in the principal component analysis dis-
carded any possible batch effect and organized the samples
following the different disease groups. Notably, all genoder-
matosis samples are located in proximity within the plot, and
are distinctly separated from controls (Fig. 1a), pointing
towards a similar transcription profile between the three geno-
dermatoses.
In order to identify the dysregulated genes, differential
expression analysis was carried out, contrasting each disease
group (RDEB, KS or XPC) vs. healthy controls (Table S3). The
number of differentially expressed genes (false discovery rate
< 005) in the different comparisons is detailed in Table 1. A
Venn diagram of the different comparisons revealed an inter-
section of 227 common dysregulated transcripts (containing
186 genes) in the three genodermatoses (Fig. 1b). Interest-
ingly, all of these transcripts (129 upregulated and 98 down-
regulated) showed not only the same expression pattern
(Fig. 1c), but also an impressive positive correlation between
the fold changes (Fig. 1d). This suggests that the common
expression profile may have a similar phenotypic impact on
the three diseases.
Common expression patterns are best understood through
the examination of enriched gene ontology terms26 and KEGG
pathways.27 This approach provides an undirected method to
highlight those biological mechanisms that could be poten-
tially relevant to the diseases. The output of this enrichment
analysis is a list of pathways and/or ontologies that involve a
statistically significant number of dysregulated genes, associ-
ated with the same biological mechanism (Fig. 2, Table S4;
see Supporting Information).
Enriched gene ontology terms for all of the diseases point
towards an abnormal relationship between the cell and its
stroma. This suggests that the contribution of dermal fibrob-
lasts to the disease lies in the altered response they exert on
the surrounding microenvironment. The dysregulated genes
were significantly associated with ECM and the cell periphery
(cellular component). Furthermore, glycosaminoglycan bind-
ing, sulfur compound binding and heparin binding – which
point towards ECM components – are over-represented
(molecular function). Apart from these terms, altered activity
of transcription factors is also noticeable, presumably associ-
ated with the observed differences in gene transcription. KEGG
pathway analysis identified common alterations in phospho-
inositol-3-kinase (PI3K)–Akt signalling, the chemokine reper-
toire and two cancer-related pathways (highlighted terms in
Table S4; see Supporting Information).
To gain a deeper insight into the altered mechanisms, we
employed the web tool hiPathia (http://hipathia.babelomics.
org) to decompose KEGG pathways into signalling circuits, by
transforming gene expression profiles into signal transduction
activity profiles.23 We found 42 overlapping circuits in the
three genodermatoses when comparing them against controls
(Fig. S1a; see Supporting Information). Effectors were associ-
ated with cell proliferation (AREG, MAPK8), transforming
growth factor (TGF)-b signalling (PITX2) and ECM–cell inter-
actions (PLAU, MAP3K4) (highlighted terms in Table S5; see
Supporting Information). A particular example of these circuits
includes activation of BCL2 – an effector molecule with an
antiapoptotic effect – initiated in multiple overexpressed nodes
and propagated through the PI3K–Akt pathway (Fig. S1b; see
Supporting Information).
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(a)
(b)
(d)
(c)
Fig 1. Differential gene expression profile. (a) Principal component analysis plot representing the global distribution of each sequenced sample,
after data processing and normalization. Disease samples tended to group together and distantly from the controls. (b) An overlapping set of 227
transcripts commonly dysregulated in all of the diseases. (c) Heat map of the normalized expression of the 227 transcripts (red, upregulated;
green, downregulated in the disease). (d) Linear regression of fold changes of the 227 transcripts (blue dots) shows an impressive positive
correlation (R2 = 0895). Axes indicate the fold-change values (logarithmic scale). RDEB, recessive dystrophic epidermolysis bullosa; KS, Kindler
syndrome; XPC, xeroderma pigmentosum complementation group C; Ctrl, healthy control.
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To identify functional associations between the 186 differ-
entially expressed genes, the STRING database24 was used to
generate PPI networks. The enrichment PPI P-value (00013)
indicates that the commonly altered genes do not represent a
randomly scattered set of proteins, but a meaningfully con-
nected set of genes in accordance with their biological
functions. Three major clusters (A, B and C) of proteins were
detected (Fig. 3). Cluster A includes a group of proteins,
mostly downregulated, involved in signalling pathways and
signal transduction (e.g. JAK3, PTK2B and PRKCQ). Interestingly,
this cluster also contains the angiotensin II receptor (AGTR1,
upregulated), a target of recent antifibrotic therapy tested in
RDEB,28 and the antioxidant enzyme extracellular superoxide
dismutase (SOD3, downregulated), previously proposed as a
repressor molecule of skin inflammation.29
Cluster B is formed predominantly by a group of tran-
scription factors (e.g. PITX2, a procollagen lysyl hydroxylase
transcription factor). Cluster C is represented by matrisome
and matrisome-associated genes (http://matrisomeproject.
mit.edu),30 implicated in the stabilization, deposition and
remodelling of the ECM (e.g. TGFBI, FN1, TNC and POSTN).
Among the minor-clustered nodes, downregulation of the
ALDH1A1 gene received our attention. This gene encodes an
antioxidant enzyme (aldehyde dehydrogenase 1A1) related
Table 1 Number of genes differentially expressed in each
genodermatosis vs. healthy controls
Comparison Underexpressed Overexpressed Total
RDEB vs. control 516 327 843
KS vs. control 196 180 376
XPC vs. control 523 509 1032
RDEB, recessive dystrophic epidermolysis bullosa; KS, Kindler
syndrome; XPC, xeroderma pigmentosum complementation
group C.
Fig 2. Enrichment analysis of differentially expressed genes. Within the specific alterations of each disease, enriched gene ontology (GO) terms
highlight common abnormalities in the three genodermatoses with respect to cell periphery, extracellular matrix (ECM) and activity of
transcription factors. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways reveal enriched categories related with cancer, phosphoinositol-
3-kinase (PI3K)–Akt and chemokine signalling. The highest-ranked categories in each disease are shown according to the P-value and percentage
of genes. RDEB, recessive dystrophic epidermolysis bullosa; KS, Kindler syndrome; XPC, xeroderma pigmentosum complementation group C; Ctrl,
healthy control; TNF, tumour necrosis factor.
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to ultraviolet protection against oxidative stress31 and is
repressed by TGF-b.32 In our analysis, ALDH1A1 is one of
the most significantly underexpressed genes in the three
diseases.
Validation of altered gene expression
Given the importance of the extracellular component – evi-
denced by enriched gene ontology terms and KEGG path-
ways – we took advantage of the STRING PPI and chose
several proteins of cluster C for validation by Western blot
(Fig. 4). In this analysis we included additional patient and
control samples not used for RNA-Seq (Table S1b; see Sup-
porting Information). In accordance with the transcriptomic
data, fibulin-1, transglutaminase-2 and ALDH1A1 were
underexpressed in the diseases, while expression of tenascin
C, periostin and TGF-b induced (TGF-bI) was increased. In
addition to the changes observed in these markers, we
found high levels of a-smooth muscle actin in all fibroblasts
of all genodermatoses, confirming their activated phenotype
(data not shown). Variability in protein expression levels in
individual fibroblasts was observed; however, there was no
evident pattern associated with body sites of origin or the
age of the donors. Abnormal expression of some of these
proteins has previously been described in RDEB fibrob-
lasts,33 but not the periostin overexpression. Thus, we
decided to study their expression by immunofluorescence in
available skin biopsy sections from patients with RDEB and
KS. The analysis showed a degree and pattern of overex-
pression similar to those seen in tenascin C, used as a posi-
tive control (Fig. 5).
Fig 3. Protein–protein interaction network of the common dysregulated genes. The three largest connected components, labelled as clusters A, B
and C, represent clusters of highly connected, biologically related proteins. The node colour is graded according to the average fold change (red,
upregulated; green, downregulated in the disease). The edge width is proportional to the STRING interaction score, which represents the
confidence for that interaction. Groups of potentially interactive proteins with fewer nodes are shown below the main clusters. Proteins without
interactions are not shown. The average node degree is 0387 and the average local clustering coefficient is 0158.
Fig 4. Western blot validation of relevant genes. Immunoblot analysis
of fibroblast cell lysates confirms the high expression of tenascin C,
periostin and transforming growth factor-b induced (TGFBI), together
with underexpression of transglutaminase-2 (TG2), aldehyde
dehydrogenase 1A1 (ALDH1A1) and fibulin-1 in samples from
patients with recessive dystrophic epidermolysis bullosa (RDEB),
xeroderma pigmentosum complementation group C (XPC) and
Kindler syndrome (KS). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as the loading control. Samples not included in
the RNA-Seq analysis are indicated by an asterisk (*). Ctrl, healthy
control.
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Identification of serum periostin as a novel biomarker in
recessive dystrophic epidermolysis bullosa
Increased levels of circulating periostin have been shown in
several noninherited fibrotic conditions including cancer.34,35
Considering the overexpression of periostin seen in vitro and
in situ, we subsequently searched for periostin in available
serum samples of patients with RDEB and healthy donors.
Consistently with the validation results, the mean  SEM cir-
culating periostin concentration was remarkably higher in
patients with RDEB (657  148 ng mL1; n = 16) than in
controls (372  033 ng mL1; n = 10) (P < 0001; Fig. 6).
This result suggests that periostin may represent a potential
biomarker in RDEB.
Discussion
Here we conducted a global gene expression analysis of
dermal fibroblasts – isolated from uninvolved skin areas of
patients with XPC, KS and RDEB – with the goal of eluci-
dating overlapping pathomechanisms in these cancer-prone
genodermatoses. Despite each disease’s gene expression sin-
gularities, our study allowed us to identify a common sig-
nature of 227 transcripts and four KEGG pathways
differentially expressed against healthy controls. Our differ-
ent bioinformatic analyses revealed the presence of three
major determinants of an activated fibroblast phenotype,
namely increased cell survival, altered TGF-b signalling and
abnormal ECM remodelling.36,37 It is known that fibroblasts
become activated when they detect adverse cues from their
surroundings (e.g. inflammation, mechanical trauma, TGF-b,
oxidative stress) and acquire a proliferative phenotype char-
acterized by aberrant secretion of ECM molecules.38 Nor-
mally, activated fibroblasts return to their original state
when the injury is resolved, through reprogramming or
apoptosis.39 However, if the insult becomes chronic, fibrob-
lasts become irreversibly active, just as occurs in CAFs and
fibrosis-associated fibroblasts.40
Fig 5. Immunofluorescence in situ validation of tenascin C (TNC) and periostin (POSTN). Skin biopsies sections from patients with recessive
dystrophic epidermolysis bullosa (RDEB) and Kindler syndrome (KS) and healthy controls (Ctrl) were stained for (a) tenascin C and (b) periostin.
Quantitation of fluorescence intensity was measured on five nonoverlapping microscopic fields per sample (ImageJ) and are represented as the
mean  SD staining intensity (MFI) per area value. The data were analysed by Student’s t-test. *P < 005; **P < 001 vs. control.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2019) 181, pp512–522
Fibroblast activation and ECM remodelling in genodermatoses, E. Chacon-Solano et al. 519
The pathway inference analysis highlighted several nodes
involving PI3K–Akt signalling activation, ultimately triggering
antiapoptotic and hyperproliferative stimuli via the BCL2 effec-
tor protein. Earlier studies on RDEB have also shown that
increased PI3K–Akt signalling mediates cell survival and cSCC
development. Indeed, it was proposed as one pharmacological
target to prevent disease progression.41 On the other hand,
ontologies and categories referred to an altered activity of the
cellular exterior, resulting in altered production of the chemo-
kine repertoire and abnormal expression of the matrisome and
matrisome-associated genes.
The involvement of aberrantly expressed ECM proteins
(e.g. tenascin C, fibulin-1, transglutaminase-2 and TGF-bI)
was previously associated with loss of C7.33,42 Overexpres-
sion of tenascin C and TGF-b activation have also been
shown in KS fibroblasts.14 To our knowledge, abnormal
expression of periostin has not yet been reported in nontu-
moral XPC, KS or RDEB fibroblasts, but it was recently
shown in RDEB cSCC biopsies.43 Periostin and tenascin C
are induced by skin damage, promoting the activation of
fibroblasts to repair the wound. Their overexpression has
been linked to pathogenic roles in chronic inflammation,
fibrosis and cancer.34,44,45
Different studies have shown that elevated levels of serum
periostin are associated with progression and disease severity
in pulmonary fibrosis,46 colorectal cancer47,48 and systemic
sclerosis.49 Our workflow from RNA-Seq to validation at the
protein level allowed us to disclose periostin as a possible sys-
temic biomarker, at least in RDEB (due to sample availability).
Currently, several experimental antifibrotic therapies are under
investigation for this disease.28 Considering the paucity of
available minimally invasive biomarkers to assess treatment
efficacy, circulating periostin may be a useful molecule to
consider. Further studies will be necessary to extend these
results to XPC and KS.
A general inferred notion from previous studies was that
causal defects, such as loss of C7 or kindlin-1, could be
responsible for the abnormal ECM expression in RDEB and KS
dermal fibroblasts.14,50,51 However, without excluding a trig-
gering effect due to the primary deficiencies, our results chal-
lenge the view of a direct genetic cause-driven effect. Rather,
they stand for the existence of a shared injury-responsive
event able to transduce the primary defect into epigenetic
changes, leading to an activated phenotype (Fig. 7). A likely
candidate appears to be TGF-b, as a large proportion of the
common dysregulated genes (e.g. TNC, POSTN, FN1, TGFBI and
ALDH1A1) are modulated by this factor. Another possible can-
didate, already shown in XPC and KS,10,52–54 is oxidative
stress, which could be able, by itself or through interaction
with TGF-b, to trigger fibroblast activation and ECM accumu-
lation.55,56 In this context, downregulation of the ALDH1A1
and SOD3 genes, encoding antioxidant enzymes, could facili-
tate oxidative stress-induced damage. Similar expression
changes in ALDH1A1 were recently described as part of the
myofibroblast-specific expression profile in mouse skin
wounds.57 In fact, an in silico comparison of our 186 dysregu-
lated genes disclosed 41 overlapping genes included in the
transcriptomic signature of mouse wound myofibroblasts.
Overexpression of POSTN and TNC stands out among these 41
genes (Fig. S2; see Supporting Information).
Fig 6. Circulating periostin levels in patients with recessive dystrophic epidermolysis bullosa (RDEB). The serum periostin concentration was
significantly higher in patients with recessive dystrophic epidermolysis bullosa (mean  SEM 657  148 ng mL1; n = 16) than in donor
controls (372  033 ng mL1; n = 10). Two independent experiments were performed for each patient and control (Ctrl) sample. ***P
< 0001.
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Examination of the exclusive transcriptional features of each
disease may also offer interesting results, concerning the dif-
ferential characteristics of each condition. However, these
specific expression changes were not the focus of this study
and should be considered separately. All in all, the common
genetic signature in fibroblasts of the three genodermatoses
shares some similarities with that found in myofibroblasts,57
wound-activated fibroblasts and cutaneous CAFs.11 The com-
mon mechanisms of the three diseases would allow considera-
tion of symptom-relief therapies currently tested in RDEB to
be used also in XPC and KS. In addition, newly elucidated
molecular targets, such as those involved in derangement of
the oxidative state, could be subject to novel pharmacological
approaches.
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